Seven generics makers [1] are high-fiving today after a federal judge declared Johnson & Johnson's patent on Alzheimer's med Razadyne invalid. The ruling is the latest development in a long-standing dispute over the patent that started when J&J sued the copycats to keep their versions off the market. Now, J&J says it will appeal [2] the judge's decision, but Barr, for one, says it's going to launch its generics straight away. So does Mylan.
The other generics makers involved are Teva--which is buying Barr [3]--plus Dr. Reddy's Laboratories, Par Pharmaceuticals, and units of Actavis and Merck KGaA. Razadyne accounted for $214 million of J&J's 2007 sales.
- read J&J's Ortho-McNeil release [4]
- check out the story [5] in the Star-Ledger
- see the Interactive Investor news [6]
- get the Wall Street Journal article [7]
Related Articles:
FDA holds back approval for J&J schizophrenia med [8]
Genentech, J&J earnings expected to rise [9]
Patent 'cliff' looms for Big Pharma [10]
BMS is lead player in patent-approval race [11]
Does the patent cliff drive innovation? [12]
Links:
[1] http://www.fiercepharma.com/story/ranbaxy-sun-race-generic-razadyne/2007-08-30
[2] http://www.jnj.com/connect/news/all/20080828_090000
[3] http://www.fiercepharma.com/story/its-teva-plus-barr-7-46b-buyout/2008-07-18
[4] http://www.fiercebiotech.com/press-releases/ortho-mcneil-neurologics-appeal-patent-ruling-razadyne
[5] http://www.nj.com/business/ledger/pharmaceutical/index.ssf?/base/business-1/1219984527278890.xml&coll=1
[6] http://www.iii.co.uk/news/?type=afxnews&articleid=6870572&action=article
[7] http://online.wsj.com/article/SB121996948904981805.html?mod=2_1566_leftbox
[8] http://www.fiercebiotech.com/story/fda-wants-more-info-approving-j-j-schizophrenia-drug/2008-08-27
[9] http://www.fiercepharma.com/story/genentech-j-j-earnings-expected-rise/2008-07-14
[10] http://www.fiercebiotech.com/story/patent-cliff-looms-for-big-pharma/2007-05-02
[11] http://www.fiercebiotech.com/story/bms-lead-player-patent-approval-race/2008-01-15
[12] http://www.fiercebiotech.com/story/spotlight-does-patent-cliff-drive-innovation/2007-08-10